CBT
VRTX icon

Crews Bank & Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Crews Bank & Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.96K Sell
12
-200
-94% -$88.6K ﹤0.01% 578
2026
Q1 		$94.7K Hold
212
– – 0.01% 296
2025
Q4 		$96.1K Hold
212
– – 0.01% 286
2025
Q3 		$83K Hold
212
– – 0.01% 305
2025
Q2 		$94.4K Hold
212
– – 0.01% 285
2025
Q1 		$103K Hold
212
– – 0.02% 270
2024
Q4 		$85.4K Buy
+212
New +$98.3K 0.01% 287

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Crews Bank & Trust's VRTX Position: Q2 2026 in Review

Crews Bank & Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 94% in Q2 2026, selling an estimated $88.6K and leaving 12 shares worth $5.96K. The position accounts for ﹤0.01% of the portfolio, ranked #578.

Crews Bank & Trust first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $103K in Q1 2025. 317 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Crews Bank & Trust held 12 shares of Vertex Pharmaceuticals worth $5.96K as of Q2 2026.
  • Crews Bank & Trust sold 200 Vertex Pharmaceuticals shares in Q2 2026, an estimated $88.6K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Crews Bank & Trust's portfolio in Q2 2026, its #578 holding.
  • Crews Bank & Trust first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Crews Bank & Trust's Vertex Pharmaceuticals position peaked at $103K in Q1 2025.
  • 317 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Crews Bank & Trust's 13F filing for Q2 2026, filed 16 Jul 2026.